22 January 2026
The Hodson Group and collaborators have developed a customised blood test that can predict, more accurately than standard scans, whether treatment has successfully eradicated diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common form of aggressive non-Hodgkin lymphoma, and is typically treated with a combination...
13 January 2026
The collaboration, announced last month, will use state-of-the-art genomics approaches in combination with machine learning methods to advance our scientific understanding of cells and tissues in health and disease. GSK is investing nearly £10 million in this ground-breaking alliance that brings together the expertise of...
CSCI celebrates fourth annual Christmas Market at JCBC!
8 December 2025
On Friday 5 December, CSCI celebrated our fourth annual Christmas Market at the Jeffrey Cheah Biomedical Centre . Partnering with our neighbours at Cancer Research UK Cambridge Institute , Cambridge Biomedical Campus , The Milner Therapeutics Institute , and Cambridge Institute of Therapeutic Immunology & Infectious...
CSCI’s Professor Sarah Teichmann elected to the US National Academy of Medicine
21 October 2025
Professor Sarah Teichmann (Chair in Stem Cell Medicine, Cambridge Stem Cell Institute, Department of Medicine, University of Cambridge) has been elected to the prestigious National Academy of Medicine in the USA. She was announced as one of 90 new regular members and 10 new international members during the annual meeting...